Trial RPCEC00000347
Publication Toledo-Romani ME, Med, 2022
Primary outcome on the report: Percentage of subjects with seroconversion ≥4-fold the anti-RBD IgG pre-vaccination level. Serum samples were collected on days 0 (baseline) and 56 from all subjects; on days 14 and 70, blood samples were taken from 50% of the participants while samples from the other 50% were collected on days 42 and 84.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.